Caricamento...
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
OBJECTIVE: To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. METHODS: In the context of COVID-19 pandemic, this was an interim analysis of an ongoing prospective observational study of patients who were stable on rituxim...
Salvato in:
| Pubblicato in: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Lippincott Williams & Wilkins
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7357416/ https://ncbi.nlm.nih.gov/pubmed/32587103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000825 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|